Citations

Clear

4510 citation(s) found for "Scott, C".

Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial
Butler, Javed , Fioretti, Francesco , McMullan, Ciaran J. , Anstrom, Kevin J. , Barash, Irina , Bonaca, Marc P. , Borentain, Maria, Corda, Stefano , Gates, Davis, Lewis, Eldrin F. , Mentz, Robert J. , O’Connor, Christopher M. , Reddy, Yogesh N.V. , Rosano, Giuseppe , Saldarriaga, Clara , Udelson, James E. , Urbinati, Alessia , Vlajnic, Vanja , Xing, Aiwen, Patel, Mahesh J., Zannad, Faı̈ez , Lam, Carolyn S P , Senni, Michele , Voors, Adriaan A , Zannad, Faiez , Nishimura, Rick , Butler, Javed , Mentz, Robert J , Teixeira, Pedro P, Ezekowitz, Justin A. , Lam, Carolyn S.P. , Lindenfeld, JoAnn , Ponikowski, Piotr , Senni, Michele , Voors, Adriaan A.

Mayo Clinic

European Heart Journal | August 15, 2025 | Volume: 47 | Issue: 6 | Pages: 683-697

10.1093/eurheartj/ehaf655 | PMID 40884032 Get It

Abstract Background and Aims In the VICTOR trial (NCT05093933), vericiguat was neutral for the primary composite endpoint of cardiovascular death or hospitalization for heart failure (HF). VICTOR was powered to independently assess cardiovascular death. This study reports detailed analysis on the effects of vericiguat on mortality. Methods VICTOR, a double-blind, placebo-controlled, randomized trial, enrolled 6105 ambulatory patients with HF and reduced ejection fraction (HFrEF) without recent worsening and randomized them to vericiguat or placebo. The main outcome for this analysis was the pre-specified secondary endpoint of cardiovascular death. All-cause death, sudden cardiac death, and death related to HF were also assessed. Results Over a median of 19.7 months (inter-quartile range 14.6–25.4), cardiovascular deaths occurred in 292 patients (5.7 deaths per 100 patient-years) and 346 patients (6.8 deaths per 100 patient-years) in the vericiguat and placebo groups, respectively (hazard ratio [HR] 0.83, 95% confidence interval [CI] 0.71–0.97; P = .020). Risk of death from any cause was lower with vericiguat vs placebo (377 [7.3 deaths per 100 patient-years] vs 440 [8.6 deaths per 100 patient-years]; HR 0.84, 95% CI 0.74–0.97; P = .015). Sudden cardiac death and HF-related deaths were lower with vericiguat vs placebo (1.6 vs 2.2 events per 100 patient-years; HR 0.75, 95% CI 0.56–0.99; P = .042 and 1.7 vs 2.4 events per 100 patient-years; HR 0.71, 95% CI 0.54–0.94; P = .016, respectively). Lower mortality rates were consistent across subgroups including baseline therapy. Consistent cardiovascular and all-cause mortality benefit was seen across baseline N-terminal pro-B-type natriuretic peptide levels. Conclusions In ambulatory well-treated participants with HFrEF, vericiguat was associated with clinically meaningful reductions in the key secondary outcome of cardiovascular death, as well as all-cause mortality.
Anatomy of the Prostate and Periprostatic Region: A Contemporary Review, From the AJR Special Series on Critical Anatomy
Cheney, Scott M, Yano, Motoyo , Gupta, Amar C, Costa, Daniel Nobrega da , Gupta, Amar C. , Shah, Rajal B.

Mayo Clinic

American Journal of Roentgenology | August 13, 2025 | Volume: 226 | Issue: 5 | Pages: No page available

10.2214/ajr.25.33454 | PMID 40801496 Get It

Platelets regulate glioblastoma growth and immunity via sex-dependent PAR4 - Estrogen receptor beta signaling
Sloan, Anthony , Bukenya, George, Tannish, Gavin P., Silver, Daniel J., Aggarwal, Anu, Lee, Juyeun, Rosoff, Daniel, Alban, Tyler J., Juric, Ivan, Parsai, Shikha, Baruah, Vargab, Tack, Liza, Navadgi, Tanvi, Reitz, Natalie, Ho, Shawn T., Badani, Aarav, Goldberg, Jessica, Yuan, Xueer, Gaboriau, Aymerick, Kamatala, Samrutha, Coker, Jesse, Kumar, Vrishabhadev Sathish, Jain, Saachi S., Scalise, Alliefair, Rajasekar, Bhairavi, Vincenti, Alex, Mulkearns-Hubert, Erin E., Horbinski, Craig M., Sloan, Andrew E., Hubert, Christopher G., Lohoff, Falk W. , Goodman, Wendy A., Miller, Tyler E., O’Connor, Christine M. , Lathia, Justin D. , Sloan, Anthony R , Luo, Jingqin , Rubin, Joshua B , Stavrou, Evi X , O'Connor, Christine M , Cameron, Scott J , Tannish, Gavin P., Silver, Daniel J., Aggarwal, Anu, Lee, Juyeun, Rosoff, Daniel, Alban, Tyler J., Juric, Ivan, Parsai, Shikha, Baruah, Vargab, Tack, Liza, Navadgi, Tanvi, Reitz, Natalie, Ho, Shawn T., Badani, Aarav, Goldberg, Jessica, Yuan, Xueer, Gaboriau, Aymerick, Kamatala, Samrutha, Coker, Jesse, Kumar, Vrishabhadev Sathish, Jain, Saachi S., Scalise, Alliefair , Rajasekar, Bhairavi, Vincenti, Alex, Mulkearns-Hubert, Erin E., Horbinski, Craig M., Sloan, Andrew E., Hubert, Christopher G., Stavrou, Evi X. , Goodman, Wendy A., Miller, Tyler E., Nieman, Marvin T. , Sangwan, Naseer , Chan, Timothy An-thy , Khorana, Alok A. , Dhawan, Andrew , Cameron, Scott J.

Mayo Clinic

No container title available | August 8, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.08.06.668464 | PMID 41959130 Get It

Abstract Sex differences in cancer outcome, including that of glioblastoma (GBM), are shaped by biological, hormonal, and immunological factors and impact disease progression, treatment responses, survival, and tumor microenvironment (TME) interactions. Platelets regulate the immune responses and tumor progression in many cancers, but it is not clear how they contribute to these sex-based differences by affecting the dynamics of the TME. Here, we show that GBM patients exhibit heightened platelet reactivity driven by PAR4 signaling. In murine GBM models, both pharmacological inhibition of PAR4 using BMS986120 and genetic deletion of PAR4 significantly prolong survival in females but not males. This survival advantage is estrogen dependent: it is preserved in chromosomal male-hormonal female mice within the four-core genotype model and is rescued in ovariectomized mice treated with estrogen. The survival benefit is TME specific and is mediated by platelet-driven enhancement of CD8⁺ T cell infiltration into the tumor. Inhibition of platelet PAR4 signaling increases calcium signaling through an estrogen-dependent interaction between PAR4 and estrogen receptor β (ERβ)—a receptor interaction not previously described. PAR4-activated platelets within the TME suppress CD8⁺ T cell function, and depletion of CD8⁺ T cells abolishes both the tumor-induced platelet reactivity and the survival benefit conferred by PAR4 inhibition. These findings establish platelet-mediated PAR4 signaling as a critical driver of tumor progression and identify sex-specific immune responses as key to therapeutic efficacy.
Connectivity as a universal predictor of tau progression in atypical Alzheimer’s disease
Bruin, Hannah de , Groot, Colin , Barthel, Henryk , Bischof, Gérard N. , Boon, Baayla D.C. , Brendel, Matthias , Cash, David M. , Coath, William , Day, Gregory S. , Dyck, Christopher H. van , Fredericks, Carolyn , Fryer, Tim D. , Graff‐Radford, Jonathan , Hobbs, Diana A. , Hoenig, Merle C. , Josephs, Keith A. , Katsumi, Yuta , Joie, Renaud La , Xiong, Chengjie , Malpetti, Maura , McGinnis, Scott M., Mecca, Adam P. , O’Brien, John T. , Putcha, Deepti , Rabinovici, Gil D. , Rahmouni, Nesrine , Rullmann, Michael , Saur, Dorothee , Servaes, Stijn , Sintini, Irene , Stevenson, Jenna , Stomrud, Erik , Strandberg, Olof, Tideman, Pontus , Touroutoglou, Alexandra , Trainer, Anne, Wekselman, Fattin, Weston, Philip S.J. , Whitwell, Jennifer L. , Yong, Keir , de Bruin, Hannah , Brendel, Matthias , Cash, David M , Coath, William , Dickerson, Bradford Clark , van Eimeren, Thilo , van der Flier, Wiesje M , Fredericks, Carolyn A , Gordon, Brian A , Graff-Radford, Jonathan , Grinberg, Lea , Hansson, Oskar , Irwin, David J , Josephs, Keith A , Katsumi, Yuta , La Joie, Renaud , Lee, Edward B , Xiong, Chengjie , Malpetti, Maura , Mohanty, Rosaleena , O'Brien, John Tiernan , Palleis, Carla , Phillips, Jeffrey S , Putcha, Deepti , Rosa-Neto, Pedro , Schott, Jonathan M , Schroeter, Matthias L , Smith, Ruben , Spina, Salvatore , Therriault, Joseph , Whitwell, Jennifer , Yong, Keir X X , Franzmeier, Nicolai , Day, Gregory S , Stomrud, Erik , Rabinovici, Gil D , Blazhenets, Ganna , Boellaard, Ronald , Doering, Elena , Drzezga, Alexander E. , Flier, Wiesje M. van der , Giessen, Elsmarieke van de , Gordon, Brian A. , Grinberg, Lea T. , Hansson, Oskar , Höglinger, Günter U. , Irwin, David J. , Jones, Peter Simon , Lee, Edward B. , Mohanty, Rosaleena , Nasrallah, Ilya M. , O’Dell, Ryan S. , Perneczky, Robert , Rowe, James B. , Sabri, Osama , Schildan, Andreas , Schott, Jonathan M. , Seeley, William W. , Servaes, Stijn , Spina, Salvatore , Visser, Denise , Wolk, David A. , Pijnenburg, Yolande A.L. , Franzmeier, Nicolai , Ossenkoppele, Rik

Mayo Clinic

Brain | August 8, 2025 | Volume: 148 | Issue: 11 | Pages: 3893-3912

10.1093/brain/awaf279 | PMID 40810361 Get It

Abstract The link between regional tau load and clinical manifestation of Alzheimer’s disease (AD) highlights the importance of characterizing spatial tau distribution across disease variants. In typical (memory-predominant) AD, the spatial progression of tau pathology mirrors the functional connections from temporal lobe epicentres. However, given the limited spatial heterogeneity of tau in typical AD, atypical (non-amnestic-predominant) AD variants with distinct tau patterns provide a key opportunity to investigate the universality of connectivity as a scaffold for tau progression. In this large-scale, multicentre study across 14 international sites, we included cross-sectional tau-PET data from 320 individuals with atypical AD (n = 139 posterior cortical atrophy/PCA-AD; n = 103 logopenic variant primary progressive aphasia/lvPPA-AD; n = 35 behavioural variant AD/bvAD; n = 43 corticobasal syndrome/CBS-AD), with a subset of individuals (n = 78) having longitudinal tau-PET data. Additionally, as an independent sample, we included regional post-mortem tau stainings from 93 atypical AD patients from two sites (n = 19 PCA-AD, n = 32 lvPPA-AD, n = 23 bvAD, n = 19 CBS-AD). Gaussian mixture modelling was used to harmonize different tau-PET tracers by transforming tau-PET standardized uptake value ratios to tau positivity probabilities (a uniform scale ranging from 0% to 100%). Using linear regression, we assessed whether brain regions with stronger resting-state functional MRI-based functional connectivity, derived from healthy elderly controls in the Alzheimer’s Disease Neuroimaging Initiative (ADNI), showed greater covariance in cross-sectional and longitudinal tau-PET and post-mortem tau pathology. Furthermore, we examined whether functional connectivity of tau-PET epicentres (i.e. the top 5% of regions with the highest baseline tau load) and tau-PET accumulation epicentres (i.e. the top 5% of regions with the highest tau accumulation rates) was associated with cross-sectional and longitudinal tau patterns. Our findings show that tau-PET epicentres aligned with clinical variants, e.g. a visual network predominant pattern in PCA-AD (‘visual AD’) and left-hemispheric temporal predominance, particularly within the language network, in lvPPA-AD (‘language AD’). Moreover, more strongly functionally connected regions showed correlated concurrent tau-PET levels (confirmed with post-mortem data) and tau-PET accumulation rates. The functional connectivity profile of tau-PET epicentres and accumulation epicentres corresponded to tau-PET progression patterns, with higher tau-PET levels and accumulation rates in functionally close regions, and lower tau-PET levels and accumulation rates in functionally distant regions. Our data are consistent with the hypothesis that tau propagation occurs along functional connections originating from local epicentres, across all AD clinical variants. Since tau proteinopathy is a major driver of neurodegeneration and cognitive decline, this finding may advance personalized medicine and participant-specific end points in clinical trials.
Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients with Resected Stages I-III Colon Cancer
Cohen, Stacey A. , Aushev, Vasily N. , Nagarajan, Arun , Wang, Chongkai , Alyunis, Fadhel, Tejani, Mohamedtaki Abdulaziz, Alqahtani, Ali , Marshall, John C., Chang, Jeremy , Manage, Kevin, George, Giby V., Malhotra, Meenakshi , Chandana, Sreenivasa R , Mehler, Shoshana , Somer, Bradley G. , Babadi, Ellie, Hanna, Diana L. , Chidharla, Anusha , Kasi, Anup , Vosoughi, Elham , Briski, Robert , Azzi, Georges, Katiyar, Vatsala , Sharma, Vivek R. , Shreenivas, Aditya , Fuqua, Jacob , Malla, Midhun , Polite, Blasé N. , Bent, Alisha H., Liu, Minetta C. , Aleshin, Alexey , Cohen, Stacey A , Laliotis, George , Jabbal, Iktej Singh , Fakih, Marwan , Sharif, Saima , Botta, Gregory P. , George, Giby V., Sharma, Shruti , Wu, Christina N. , Dayyani, Farshid , Pedersen, Katrina S. , Chan, Abigail Sy , Chakrabarti, Sakti , Bent, Alisha , Rabinowitz, Matthew , Jurdi, Adham Adel , Kopetz, Scott

Mayo Clinic

Annals of Surgery | August 7, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/sla.0000000000006887 | PMID 40772634 Get It

Objective: In this study, we evaluate the utility of ctDNA analysis in a large cohort of patients for whom ctDNA testing was ordered commercially with real-world application. Summary Background Data: Circulating tumor DNA (ctDNA) has emerged as a prognostic and predictive biomarker for assessing post-surgical molecular residual disease (MRD) and response to treatment. Methods: A real-world data analysis was performed using commercial ctDNA testing (SignateraTM) from patients (N=795, n=5,971 plasma samples) with stage I-III colon cancer treated at multiple US institutions. The association of ctDNA detection within the MRD window, during surveillance, and the impact of ACT was correlated with patient outcomes. Results: ctDNA-positive patients during the MRD window and surveillance showed significantly shorter DFS compared to ctDNA-negative patients (hazard ratio (HR): 9.85, P<0.0001; HR: 26.91, P<0.0001). Multivariate analysis of the MRD window revealed ctDNA-positivity as the most significant factor associated with inferior DFS (adjHR: 7.7, P<0.001). MRD-positive patients who received ACT showed improved DFS compared to patients observed post-surgery (adjHR: 6.1, FDR adj P=0.0007). No ACT benefit was observed in MRD-negative patients (adj HR: 1.20, FDR adj P=0.768). On evaluating ctDNA dynamics from MRD to surveillance, patients who remained ctDNA-positive or converted from negative to positive showed a significantly inferior DFS (HR: 34.40, P<0.0001; HR: 13.65, P<0.0001) compared to persistently ctDNA-negative patients. Conclusions: Postsurgical ctDNA detection is prognostic of relapse and potentially predictive of ACT benefit in patients with resectable colon cancer, which may enable personalized surveillance, intervention, and/or trial options, ultimately improving patient outcomes.
Rethinking psychological treatment targets for pediatric rumination syndrome: Clinical implications from a case series analysis
Anastasiadis, William A. , Gloe, Lilianne M. , Johnson-Kwochka, Annalee V. , Diest, Ashley M. Kroon Van , Lagges, Ann, Wagoner, Scott T. , Williams, Amy E. , Sparks, Brandon , Gilbert, Elaine

Mayo Clinic

JPGN Reports | August 7, 2025 | Volume: 6 | Issue: 4 | Pages: 382-386

10.1002/jpr3.70074 | PMID 41245029 Get It

Abstract Rumination syndrome (RS) is a common pediatric disorder of gut–brain interaction. However, a dearth of research on efficacious treatment to help guide clinical decision‐making remains. Thus, relying on well‐established treatment recommendations for other conditions with similar mechanisms or symptom profiles may be helpful; for example, conceptualizing RS treatment targets to address it as a “tic disorder of the gut” could be beneficial. To demonstrate the clinical utility of this conceptualization, we presented two cases that provide broad implications for treating pediatric RS. In both cases, akin to pediatric tic and related disorders, cognitive distress and physical discomfort were alleviated temporarily by rumination episodes. Thus, we recommend a targeted diagnostic assessment, including a functional analysis incorporating a transdiagnostic evaluation of symptoms. Close comanagement with specialty physicians and psychologists is also highly recommended. The patients represent complex yet standard cases seen in pediatric psychology outpatient clinics, suggesting the clinical utility of implications for psychologists and allied health professionals.
Factors Influencing the Duration From the Initiation of Surgical Evaluation to Final Intervention in Pediatric Epilepsy Surgery
Al‐Ramadhani, Ruba , Hyslop, Ann , Caraway, Avery Robert, Ostendorf, Adam P. , Alexander, Allyson , Depositario‐Cabacar, Dewi F., Karia, Samir , Tatachar, Priyamvada, Bolton, Jeffrey , Pichon, P, Shrey, Daniel W. , Romanowski, Erin Fedak , Auguste, Kurtis I. , Bernardo, Danilo , Singh, Rani K., Reddy, Shilpa B. , Ganesh, Abhinaya, Ciliberto, Michael A. , Samanta, Debopam , Arredondo, Kristen H. , Marashly, Ahmad , Wagner, Janelle L. , Miller, D. , Galán, Fernando , Perry, Μ. Scott , Caraway, Avery R. , Wong-Kisiel, Lily C. , Gonzalez-Giraldo, Ernesto , Samanta, Debopam , Galan, Fernando N , Hyslop, Ann , Miller, Derryl J , Caraway, Avery Robert , Novotny, Edward J. , Eschbach, Krista , Wong‐Kisiel, Lily C. , Depositario‐Cabacar, Dewi, Oluigbo, Chima , Karakas, Cemal , Tatachar, Priyamvada , McNamara, Nancy , Gonzalez‐Giraldo, Ernesto , Javarayee, Pradeep , Lin, Jenny J. , Coryell, Jason , Ganesh, Abhinaya, Grinspan, Zachary M. , Armstrong, Dallas , Abel, Taylor J.

Mayo Clinic

Annals of the Child Neurology Society | August 6, 2025 | Volume: 3 | Issue: 3 | Pages: 188-200

10.1002/cns3.70027 | PMID 42563855 Get It

ABSTRACT Rationale Longer duration of epilepsy before surgery is a predictor of poor outcome. While referral delays of surgical candidates are well documented, factors causing delay during the presurgical evaluation remain unclear and may vary depending on institutional characteristics. By benchmarking the duration of presurgical evaluation across multiple centers and identifying patient and evaluation characteristics contributing to duration, we can ascertain best practices and address modifiable contributors to reduce delays. Methods We queried the Pediatric Epilepsy Research Consortium Surgery Database, a prospective, observational multicenter study enrolling children 0–18 years at 27 US pediatric epilepsy centers, for all patients undergoing initial presurgical evaluation for drug‐resistant epilepsy (DRE). We included patients with completed evaluations and data on duration from initiation of presurgical evaluation to final surgical decision. We compared patient characteristics and evaluation components between those with long duration evaluations (> 75% quartile) and those with short evaluations (< 25% quartile). Akaike information criteria selection identified variables associated with longer duration. From these, we developed a logistic prediction model for evaluation duration, using a random 80/20 training/testing split of the entire cohort. The model was tested among institutions with ≥ 10 patients in the cohort to assess its accuracy in predicting long durations. Linear models for each site assessed each variable's impact on duration. Variables with < 10% of the patient population at each site were excluded. Beta values were compared to identify intra‐ and inter‐institution variability and to delineate institutions with the shortest added duration for each variable. Results Of 2318 patients undergoing surgical evaluation, 1655 (71%) from 23 sites had complete data. Median evaluation duration was 8 weeks (interquartile range 3–22); 453 (27%) were short‐duration evaluations and 414 (25%) were long‐duration evaluations. Multiple patient and evaluation characteristics were associated with duration (Table 1). Table 6 provides the average duration each variable contributes to evaluation by site, highlighting the shortest durations compared with other groups. Conclusions Duration of presurgical evaluation for DRE can be accurately modeled using multiple patient characteristics and testing strategies commonly employed in epilepsy surgery evaluations. This predictive model can not only estimate evaluation duration but also identify opportunities to improve systemic efficiency. Institution‐level modeling identifies specific program strengths, providing an opportunity to learn from successful processes. Subsequent research will focus on institutional process mapping to better understand systemic practices that lead to improved efficiencies, then sharing these processes across the consortium to shorten evaluation durations.
NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025
Abu‐Rustum, Nadeem R. , Campos, Susana M. , Amarnath, Sudha, Barber, Emma L. , Bradley, Kristin , Brooks, Rebecca , Chino, Junzo , Chon, Hye Sook, Damast, Shari , Fisher, Christine M. , Frederick, Peter J., Gaffney, David K. , Giuntoli, Robert , Glaser, Scott , Howitt, Brooke E. , Landrum, Lisa M. , Mantia-Smaldone, Gina , Mariani, Andrea , Nagel, Christa , Nieto, Karina , Nwachukwu, Chika , Podoll, Mirna, Rodabaugh, Kerry J. , Salani, Ritu , Schorge, John O., Schuetze, Scott M. , Siedel, Jean , Sisodia, Rachel, Soliman, Pamela T. , Ueda, Stefanie , Urban, Renata R. , Wyse, Emily , McMillian, Nicole R., Arend, Rebecca C. , Crispens, Marta Ann , Gaillard, Stéphanie , Lea, Jayanthi Sivasothy , Lee, Nita Karnik , Mutch, David G. , Nekhlyudov, Larissa , Sambandam, Vaishnavi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 5, 2025 | Volume: 23 | Issue: 8 | Pages: 284-291

10.6004/jnccn.2025.0038 | PMID 40763788 Get It

The NCCN Guidelines for Uterine Neoplasms provide recommendations for diagnostic workup, clinical staging, and treatment options for patients with endometrial cancer and uterine sarcoma. The NCCN Cervical Uterine Panel meets at least annually to review comments from reviewers within their institutions; examine relevant new data from publications, abstracts, and recent FDA approvals; and reevaluate and update recommendations. These NCCN Guidelines Insights summarize the panel’s deliberations on the new FIGO 2023 staging system and updates on the new systemic therapy recommendations for the management of endometrial cancer.
A Novel You Only Listen Once (YOLO) Deep Learning Model for Automatic Prominent Bowel Sounds Detection: Feasibility Study in Healthy Subjects
Kalahasty, Rohan, Yerrapragada, Gayathri, Lee, Jieun , Gopalakrishnan, Keerthy, Kaur, Avneet , Muddaloor, Pratyusha, Sood, Divyanshi, Parikh, Charmy, Gohri, Jay , Panjwani, Gianeshwaree Alias Rachna , Asadimanesh, Naghmeh, Ansari, Rabiah Aslam, Rapolu, Swetha, Karuppiah, Shiva Sankari, Dasari, Vijaya M., Helgeson, Scott A. , Arunachalam, Shivaram P. , Helgeson, Scott A , Arunachalam, S P , Panjwani, Gianeshwaree Alias Rachna , Yerrapragada, Gayathri, Ansari, Rabiah Aslam, Elangovan, Poonguzhali , Akshintala, Venkata S.

Mayo Clinic

Sensors | August 4, 2025 | Volume: 25 | Issue: 15 | Pages: 4735

10.3390/s25154735 | PMID 40807899 Get It

Accurate diagnosis of gastrointestinal (GI) diseases typically requires invasive procedures or imaging studies that pose the risk of various post-procedural complications or involve radiation exposure. Bowel sounds (BSs), though typically described during a GI-focused physical exam, are highly inaccurate and variable, with low clinical value in diagnosis. Interpretation of the acoustic characteristics of BSs, i.e., using a phonoenterogram (PEG), may aid in diagnosing various GI conditions non-invasively. Use of artificial intelligence (AI) and improvements in computational analysis can enhance the use of PEGs in different GI diseases and lead to a non-invasive, cost-effective diagnostic modality that has not been explored before. The purpose of this work was to develop an automated AI model, You Only Listen Once (YOLO), to detect prominent bowel sounds that can enable real-time analysis for future GI disease detection and diagnosis. A total of 110 2-minute PEGs sampled at 44.1 kHz were recorded using the Eko DUO® stethoscope from eight healthy volunteers at two locations, namely, left upper quadrant (LUQ) and right lower quadrant (RLQ) after IRB approval. The datasets were annotated by trained physicians, categorizing BSs as prominent or obscure using version 1.7 of Label Studio Software®. Each BS recording was split up into 375 ms segments with 200 ms overlap for real-time BS detection. Each segment was binned based on whether it contained a prominent BS, resulting in a dataset of 36,149 non-prominent segments and 6435 prominent segments. Our dataset was divided into training, validation, and test sets (60/20/20% split). A 1D-CNN augmented transformer was trained to classify these segments via the input of Mel-frequency cepstral coefficients. The developed AI model achieved area under the receiver operating curve (ROC) of 0.92, accuracy of 86.6%, precision of 86.85%, and recall of 86.08%. This shows that the 1D-CNN augmented transformer with Mel-frequency cepstral coefficients achieved creditable performance metrics, signifying the YOLO model’s capability to classify prominent bowel sounds that can be further analyzed for various GI diseases. This proof-of-concept study in healthy volunteers demonstrates that automated BS detection can pave the way for developing more intuitive and efficient AI-PEG devices that can be trained and utilized to diagnose various GI conditions. To ensure the robustness and generalizability of these findings, further investigations encompassing a broader cohort, inclusive of both healthy and disease states are needed.
A Prospective Video-Reflexive Ethnographic Study of Direct Patient-Pathologist Interactions With Heart and Lung Allograft Recipients
Roden, Anja C. , Asiedu, Gladys B. , Regnier, Angela K., Bois, Melanie C. , Yi, Eunhee S. , Larson, Nicole L. , PETERS, K. S., Aubry, Marie Christine, Maleszewski, Joseph J. , Boland, Jennifer M. , Lo, Ying‐Chun , Peters, Kristina L., Zhu, Xuan , Scott, John P.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | August 4, 2025 | Volume: 150 | Issue: 2 | Pages: 129-135

10.5858/arpa.2025-0164-oa | PMID 40755266 Get It

Context.— A clinic was created for patients to review their explanted organs with a pathologist. Objective.— To prospectively investigate the benefits of this type of clinic as perceived by both transplant patients and their pathologists. Design.— In this prospective study, patients participated in a videotaped viewing of heart and/or lung explants by the patient and their guest(s) and pathologist (December 2017–August 2022). Patients received a 3D-printed replica of their explant. After viewing the explanted organ, patients and their guests participated in an interview to assess their experiences. Video-reflexive ethnography was used by pathologists for data collection and practice improvement. Results.— Of 143 patients who viewed their explanted organ, 21 patients consented to having the organ-viewing session taped and to participate in a postviewing interview. The study group was comprised of 12 men; the median age was 57.5 years (range, 29–67 years). Five pathologists took part in reflexive sessions. The clinics were viewed positively by patients, providing an opportunity to better understand their disease. Pathologists had a similarly positive experience and gained important insights to patient journeys. Proposals for improvement were brought forward from both patients and pathologists. Conclusions.— Video-reflexive ethnography provided the opportunity for patients and pathologists to reflect on patient-pathology clinic appointments. This work serves as a template to build out pathology-based clinics.